All Antibiotics articles – Page 2
-
NewsNew AI method maps how tuberculosis drugs destroy bacteria
Scientists at Tufts University have developed an AI tool that demonstrates how tuberculosis drugs kill bacteria – an advancement that could speed-up the discovery of shorter, more effective treatments.
-
NewsHow FtsZ and ZapA proteins drive bacterial cell division
Japanese researchers have discovered how the bacterial proteins FtsZ and ZapA work together to drive cell division – a discovery that could guide the development of new antibacterial treatments.
-
NewsDiscovery of hidden survival mechanism in MRSA points to new drug targets
In the fight against antibiotic-resistant bacteria, researchers at Michigan State University (MSU) have made a discovery that could change how we target deadly pathogens like Staphylococcus aureus and its drug-resistant strain - MRSA.
-
NewsMitochondria: melanoma’s hidden vulnerability
Scientists at Lund University have shown that aggressive melanoma tumours are driven by overactive mitochondrial processes – revealing a potential treatment strategy using drugs already approved for other conditions.
-
NewsDual-action therapy clears MDR bacteria in preclinical models
Centauri Therapeutics has published data showing that CTX-09’s ability effectively clears drug-resistant Gram-negative bacteria through a novel dual mechanism, marking a promising development for new infection therapies.
-
ArticleStrategic planning in ADC development: insights from Lonza
Preclinical and clinical development are critical to the success of ADCs, where early strategic decisions regarding manufacturability and scalability can make or break a project. Iwan Bertholjotti of Lonza emphasises the importance of proactive planning to avoid costly delays and ensure smooth progress towards clinical success.
-
ArticleSpirulina’s role in shaping the future of preventative biologics
From law to biotech, Brian Finrow's career path has been anything but conventional. As Co-founder and CEO of Lumen Bioscience, he’s steering the company’s innovative approach to drug discovery, focusing on preventative biologics that offer scalable, cost-effective solutions. Find out how Finrow's unique spirulina-based platform is changing the way we ...
-
NewsScientists turn superbug MRSA into treatable infection
Researchers have discovered a breakthrough method to silence MRSA's drug resistance, restoring its sensitivity to standard antibiotics and offering new hope in the fight against superbugs.
-
NewsGlox Therapeutics secures £500K to develop antibiotics for cystic fibrosis
Glox Therapeutics has received a portion of a £3 million fund to combat antimicrobial resistance in cystic fibrosis patients.
-
NewsUVA’s computer models target antibiotics to combat resistance
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
-
NewsPhage therapy: A step forward in the fight against antibiotic resistance
A new study shows how phages, viruses that kill bacteria, can coexist on a single bacterial strain. This offers valuable insights for developing more effective therapies against antibiotic-resistant infections.
-
NewsE. coli alters ribosomes to survive antibiotic treatment
New study shows E. coli resists antibiotics by modifying its ribosome structure, blocking drug binding and enabling growth despite treatment.
-
NewsP. aeruginosa infection method elucidated with microtissue model
Researchers found, using human respiratory epithelium organoids, that P. aeruginosa breaches respiratory epithelia by goblet cell invasion.
-
ArticleRecce Pharmaceuticals’ synthetic approach to combatting AMR
As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a ...
-
NewsNew AI model could help to overcome antibiotic resistance
Six molecules that had potent antibacterial effect against one of the world’s most dangerous antibiotic-resistant bacteria were generated.
-
NewsNew antibiotic overcomes antimicrobial mechanisms
Researchers have created a novel molecule, which has an improved ability to bind to bacterial ribosomes, with a completely synthetic system.
-
NewsIncreased persister cells production leads to antibiotic resistance
Using clinical E. coli bacteraemia isolates, researchers found that high-persister mutants evolved which contributed to antibiotic failure.
-
NewsDisrupting the mechanism pathogens use to infect host cells
New understanding of the communication system between pathogens and host cells provides a way to avoid antimicrobial resistance.
-
ArticleAntimicrobial resistance with Recce Pharmaceuticals
In this exclusive interview, Drug Target Review's Taylor Mixides interviews James Graham, CEO of Recce Pharmaceuticals, they explore the company's approach to combat the growing global threat of antimicrobial resistance (AMR). Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of ...
-
News
Genetic scar left in the genome of bacteria
New study reveals how pneumonia cells become resistant to penicillin through evolutionary gateway.
- Previous Page
- Page1
- Page2
- Page3
- Next Page